Unibest

Pharmaceutical intermediates

Lenalidomide Intermediates

2 pharmaceutical intermediates for Lenalidomide. Indication: Marginal zone B-cell lymphoma; Diffuse large B-cell lymphoma; Adult T-cell leukemia lymphoma; Multiple myeloma.

提交项目All intermediates

About Lenalidomide

Originator
Celgene Corporation
Indication
Marginal zone B-cell lymphoma; Diffuse large B-cell lymphoma; Adult T-cell leukemia lymphoma; Multiple myeloma
Approved Date
06/29/2006
DS/DP
04/27/2027

Available intermediates

2 intermediates currently listed for Lenalidomide. Request specifications, documentation or a quotation for any item below.

Lenalidomide intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
methyl 2-(bromomethyl)-3-nitrobenzoate98475-07-1//
3-aminopiperidine-2,6-dione hydrochloride24666-56-6/2686-86-4//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Lenalidomide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →